Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anthrax
Elusys' Anthim(TM) Dramatically Improves Survival of Animals Treated After Active Anthrax Infection
May 9th, 2008
Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, announced pivotal animal efficacy results of Anthim(TM), a high-affinity humanized and deimmunized monoclonal antibody targeting the anthrax toxin protective antigen. Elusys' Anthim is designed as a "just in time" anthrax therapeutic that can be administered by a single, rapid intramuscular injection and has the potential to provide quick protection against the lethal effects of anthrax toxin. In this study, primates were infected with a highly lethal dose of aerosolized anthrax...
Source: Health Business Week (2008-05-09)
|
